JP2023551009A5 - - Google Patents

Info

Publication number
JP2023551009A5
JP2023551009A5 JP2023532513A JP2023532513A JP2023551009A5 JP 2023551009 A5 JP2023551009 A5 JP 2023551009A5 JP 2023532513 A JP2023532513 A JP 2023532513A JP 2023532513 A JP2023532513 A JP 2023532513A JP 2023551009 A5 JP2023551009 A5 JP 2023551009A5
Authority
JP
Japan
Prior art keywords
approximately
composition according
pp6m
paliperidone palmitate
pp3m
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023532513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551009A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/062198 external-priority patent/WO2022111860A1/en
Publication of JP2023551009A publication Critical patent/JP2023551009A/ja
Publication of JP2023551009A5 publication Critical patent/JP2023551009A5/ja
Pending legal-status Critical Current

Links

JP2023532513A 2020-11-30 2021-05-07 持続放出パリペリドン注射可能製剤に関連する投与レジメン Pending JP2023551009A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119363P 2020-11-30 2020-11-30
US63/119,363 2020-11-30
PCT/EP2021/062198 WO2022111860A1 (en) 2020-11-30 2021-05-07 Dosing regimens associated with extended release paliperidone injectable formulations

Publications (2)

Publication Number Publication Date
JP2023551009A JP2023551009A (ja) 2023-12-06
JP2023551009A5 true JP2023551009A5 (OSRAM) 2024-05-17

Family

ID=75904921

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023532513A Pending JP2023551009A (ja) 2020-11-30 2021-05-07 持続放出パリペリドン注射可能製剤に関連する投与レジメン

Country Status (19)

Country Link
US (2) US11439647B2 (OSRAM)
EP (1) EP4025189B1 (OSRAM)
JP (1) JP2023551009A (OSRAM)
KR (1) KR20230116836A (OSRAM)
CN (1) CN116528836A (OSRAM)
AU (1) AU2021389587A1 (OSRAM)
CA (1) CA3203015A1 (OSRAM)
DK (1) DK4025189T3 (OSRAM)
ES (1) ES2981035T3 (OSRAM)
FI (1) FI4025189T3 (OSRAM)
HR (1) HRP20240800T1 (OSRAM)
HU (1) HUE067072T2 (OSRAM)
IL (1) IL303252A (OSRAM)
LT (1) LT4025189T (OSRAM)
MX (1) MX2023006368A (OSRAM)
PL (1) PL4025189T3 (OSRAM)
RS (1) RS65815B1 (OSRAM)
TW (1) TW202222317A (OSRAM)
WO (1) WO2022111860A1 (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
CA3203015A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
CN116528837B (zh) 2020-11-30 2025-03-14 詹森药业有限公司 用于确保棕榈酸帕潘立酮制剂再悬浮的方法
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254556A (en) 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
US5158952A (en) 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
TW487572B (en) 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌3−[2−[4−(6−フルオロ−1,2−ベンズイソオキサゾール−3−イル)−1−ピペリジニル]エチル]−6,7,8,9−テトラヒドロ−9−ヒドロキシ−2−メチル−4H−ピリド[1,2−a]ピリミジン−4−オンパルミチン酸エステルの製造
CN101932327A (zh) 2007-12-19 2010-12-29 詹森药业有限公司 与长效注射用帕潘立酮酯相关的给药方案
WO2011042453A1 (en) 2009-10-06 2011-04-14 Ascendis Pharma As Subcutaneous paliperidone composition
KR20120116401A (ko) 2009-10-30 2012-10-22 얀센 파마슈티카 엔.브이. 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법
EP2529757B1 (en) 2011-05-31 2014-01-08 Laboratorios Farmaceuticos Rovi, S.A. Paliperidone implant formulation
WO2016157061A1 (en) 2015-03-31 2016-10-06 Wockhardt Limited Aseptic wet milling process for paliperidone palmitate
FI3744326T3 (fi) 2015-04-07 2024-02-02 Janssen Pharmaceutica Nv Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille
ES3037855T3 (en) 2017-12-14 2025-10-08 SpecGx LLC One step milling process for preparing micronized paliperidone esters
SMT202400077T1 (it) 2020-11-30 2024-03-13 Janssen Pharmaceutica Nv Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato
CA3203015A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations
CN116528837B (zh) 2020-11-30 2025-03-14 詹森药业有限公司 用于确保棕榈酸帕潘立酮制剂再悬浮的方法
MX2023006370A (es) 2020-11-30 2023-08-07 Janssen Pharmaceutica Nv Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada.
MX2024002215A (es) 2021-08-20 2024-05-10 Janssen Pharmaceutica Nv Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada.

Similar Documents

Publication Publication Date Title
JP2023552329A5 (OSRAM)
JP3701870B2 (ja) 末梢血管疾患治療のための9−デオキシ−2’,9−α−メタノ−3−オキサ−4,5,6−トリノール−3,7−(1’,3’−インターフェニ
JP2023552149A5 (OSRAM)
US6312717B1 (en) Method for treatment of anxiety and depression
JP3623962B2 (ja) ヒドロキソコバラミンの鼻中投与用医薬組成物
FI4025189T3 (fi) Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia
FI4025188T3 (fi) Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia
BR112012015202B1 (pt) uso de iota- e/ou kappa-carragenano junto com um inibidor da neuraminidase, e, composição farmacêutica
JP2012533554A5 (OSRAM)
JP7594045B2 (ja) 薬学的組成物
JP2023535744A5 (OSRAM)
AU618997B2 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
FI4025187T3 (fi) Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia
JPH10158169A (ja) 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法
US20230181704A1 (en) Anti-sars-cov-2 virus agent antiprovir
EA004474B1 (ru) Комбинированное лечение заболевания цнс, особенно болезни паркинсона, путём совместного введения каберголина и прамипексола
JP2023543439A5 (OSRAM)
AU2006269628B2 (en) Pharmaceutical formulations of endo-N-(9- methyl-9-azabicyclo[3 .3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
AU2011274652A1 (en) A combination composition comprising ibuprofen and paracetamol
Ananth et al. Benztropine psychosis
JP2627914B2 (ja) プロスタグランジン類の選択的作用増強剤
JPH0213644B2 (OSRAM)
EP1518554B1 (en) Pharmaceutical composition for the treatment of hyperhomocysteinemia
JPH0753388A (ja) 骨代謝改善剤
HUP9903723A2 (hu) Ginkgolidok alkalmazása membráneszpresszió gátlására